A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery

Vaccine
Mohan KarkadaMarc Mansour

Abstract

Nucleic acid vaccines represent a promising alternative to killed bacterial antigen, recombinant protein or peptide vaccines for infectious diseases and cancer immunotherapy. Although significant advances are made with DNA vaccines in animal studies, there are severe limitations to deliver these vaccines effectively and considerable reservations exist about current methods used. In this study, a liposome-based vaccine platform, VacciMax (VM), and its modified water-free version, DepoVax (DPX), were tested for their ability to improve in vivo delivery of plasmid DNA (pDNA), mRNA and siRNA. Subcutaneously injected pDNA for IL12 and pDNA as well as mRNA for green fluorescent protein (GFP) in VM/DPX significantly enhanced their in vivo expression. Enhanced IL12 secretion and GFP expression was restricted to CD11b(+) and CD11c(+) antigen-presenting cells, but not B cells. Further, significant inhibition of plasmid/antigen-induced IL12 secretion was seen after injection of IL12-siRNA in VM. These findings suggest VM and DPX to be promising means of delivering nucleic acid vaccines in vivo, and warrant further studies on their role in inducing effective immune responses.

References

Mar 23, 1990·Science·J A WolffP L Felgner
Jun 3, 2000·Annual Review of Immunology·S GurunathanR A Seder
Mar 7, 2003·Gene Therapy·H Herweijer, J A Wolff
Feb 17, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark A Behlke
Apr 25, 2007·Journal of Translational Medicine·Marc MansourPirouz Daftarian
Nov 17, 2007·Immunology Letters·Benjamin WeideSteve Pascolo
Jun 7, 2008·Human Vaccines·Cevayir CobanKen J Ishii
Oct 7, 2008·Cancer Immunology, Immunotherapy : CII·Paula J WhittingtonWei-Zen Wei
Nov 27, 2008·The Journal of Clinical Investigation·Mojca SkoberneNina Bhardwaj
Jan 1, 2007·Recent Patents on Drug Delivery & Formulation·Aliasgar ShahiwalaMansoor M Amiji
Apr 21, 2009·Future Oncology·Pawel KalinskiRavikumar Muthuswamy
May 9, 2009·Advanced Drug Delivery Reviews·Yu-Kyoung Oh, Tae Gwan Park

❮ Previous
Next ❯

Citations

Apr 1, 2011·Drug Delivery and Translational Research·Deepika JainRanjit Singh
Jul 14, 2012·Langmuir : the ACS Journal of Surfaces and Colloids·Tiago A BalbinoLucimara G de La Torre
Feb 9, 2012·Expert Review of Vaccines·Fadi Saade, Nikolai Petrovsky
Oct 26, 2011·Journal of Drug Targeting·Sara MovassaghianVladimir P Torchilin
Mar 19, 2011·Expert Opinion on Drug Delivery·Malou Henriksen-LaceyDennis Christensen
Nov 3, 2015·Biotechnology Advances·Lívia de Paula PeresMarcelo José Barbosa Silva
Dec 29, 2015·Expert Review of Vaccines·Lei Li, Nikolai Petrovsky
Jun 13, 2017·Human Vaccines & Immunotherapeutics·John J SuschakConnie S Schmaljohn
Sep 25, 2017·Expert Review of Vaccines·Hanadi SalibaSoulaima Chamat
Jun 25, 2020·Pharmaceutics·Lisa Rahnfeld, Paola Luciani
Feb 16, 2021·Advanced Materials·Eunjung KimSeungjoo Haam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.